Dissecting the human serum antibody response to secondary dengue virus infections

PLoS Neglected Tropical Diseases

Volumn 11, Issue 5, 2017, Pages

  Patel, Bhumi ^a   Longo, Patti ^a   Miley, Michael J ^a   Montoya, Magelda ^b   Harris, Eva ^b   de Silva, Aravinda M ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISERUM; CROSS REACTING ANTIBODY; EPITOPE; NEUTRALIZING ANTIBODY; VIRUS ENVELOPE PROTEIN; VIRUS ANTIBODY;

ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; DENGUE; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; MEDICAL CARE; NICARAGUAN; PROSPECTIVE STUDY; ADOLESCENT; ANTIBODY PRODUCTION; BLOOD; CHILD; CLASSIFICATION; COHORT ANALYSIS; CROSS REACTION; DENGUE VIRUS; IMMUNOLOGY; INFANT; MIXED INFECTION; PRESCHOOL CHILD; SEROTYPE; TRAVEL; VIROLOGY;

ADOLESCENT; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIBODY FORMATION; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; COINFECTION; CROSS REACTIONS; DENGUE; DENGUE VIRUS; HUMANS; INFANT; SEROGROUP; TRAVEL;

EID: 85020468007     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0005554     Document Type: Article

References (37)

1. Fields BN, Knipe DM, Howley PM, Griffin DE, Fields virology. 4th ed. Philadelphia: Lippincott Williams & Wilkins; 2001. xix, 3087 p. p.
2. Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, et al. The global distribution and burden of dengue. Nature. 2013;496(7446):504–7. Epub 2013/04/09. doi: 10.1038/nature12060 23563266.
3. Halstead SB, Dengue. London Hackensack, NJ: Imperial College Press; Distributed by World Scientific Pub.; 2008. xx, 485 p. p.
4. Simmons CP, Farrar JJ, van Vinh Chau N, Wills B, Dengue. New England Journal of Medicine. 2012;366(15):1423–32. doi: 10.1056/NEJMra1110265 22494122.
5. Guzman MG, Gubler DJ, Izquierdo A, Martinez E, Halstead SB, Dengue infection. Nat Rev Dis Primers. 2016;2:16055. doi: 10.1038/nrdp.2016.55 27534439.
6. Imrie A, Meeks J, Gurary A, Suhkbaatar M, Truong TT, Cropp CB, et al. Antibody to Dengue 1 Detected More Than 60 Years after Infection. Viral immunology. 2007;20(4):672–5. doi: 10.1089/vim.2007.0050 18158740.
7. Murphy BR, Whitehead SS, Immune response to dengue virus and prospects for a vaccine. Annu Rev Immunol. 2011;29:587–619. doi: 10.1146/annurev-immunol-031210-101315 21219187.
8. de Alwis R, Smith SA, Olivarez NP, Messer WB, Huynh JP, Wahala WM, et al. Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions. Proceedings of the National Academy of Sciences. 2012;109(19):7439–44.
9. Fibriansah G, Tan JL, Smith SA, Alwis AR, Ng T-S, Kostyuchenko VA, et al. A potent anti-dengue human antibody preferentially recognizes the conformation of E protein monomers assembled on the virus surface. EMBO Molecular Medicine. 2014;6(3):358–71. doi: 10.1002/emmm.201303404 24421336.
10. Fibriansah G, Tan JL, Smith SA, de Alwis R, Ng TS, Kostyuchenko VA, et al. A highly potent human antibody neutralizes dengue virus serotype 3 by binding across three surface proteins. Nat Commun. 2015;6:6341. Epub 2015/02/24. doi: 10.1038/ncomms7341 25698059;
11. Smith SA, de Alwis AR, Kose N, Jadi RS, de Silva AM, Crowe JE, JrIsolation of dengue virus-specific memory B cells with live virus antigen from human subjects following natural infection reveals the presence of diverse novel functional groups of antibody clones. J Virol. 2014;88(21):12233–41. doi: 10.1128/JVI.00247-14 25100837;
12. Teoh EP, Kukkaro P, Teo EW, Lim APC, Tan TT, Yip A, et al. The Structural Basis for Serotype-Specific Neutralization of Dengue Virus by a Human Antibody. Science Translational Medicine. 2012;4(139):139ra83-ra83.
13. Halstead SB, Pathogenesis of Dengue: Challenges to Molecular Biology. Science. 1988;239(4839):476. 3277268; 00113967.
14. Roehrig JT, Antigenic Structure of Flavivirus Proteins. Advances in Virus Research. Volume 59: Academic Press; 2003. p. 141–75.
15. Kuhn RJ, Zhang W, Rossmann MG, Pletnev SV, Corver J, Lenches E, et al. Structure of Dengue Virus: Implications for Flavivirus Organization, Maturation, and Fusion. Cell. 2002;108(5):717–25. http://dx.doi.org/10.1016/S0092-8674(02)00660-8. 11893341
16. Schieffelin JS, Costin JM, Nicholson CO, Orgeron NM, Fontaine KA, Isern S, et al. Neutralizing and non-neutralizing monoclonal antibodies against dengue virus E protein derived from a naturally infected patient. Virology Journal. 2010;7:28-. doi: 10.1186/1743-422X-7-28 20132551.
17. Lai C-Y, Tsai W-Y, Lin S-R, Kao C-L, Hu H-P, King C-C, et al. Antibodies to Envelope Glycoprotein of Dengue Virus during the Natural Course of Infection Are Predominantly Cross-Reactive and Recognize Epitopes Containing Highly Conserved Residues at the Fusion Loop of Domain II. Journal of Virology. 2008;82(13):6631–43. doi: 10.1128/JVI.00316-08 18448542.
18. Beltramello M, Williams KL, Simmons CP, Macagno A, Simonelli L, Quyen NTH, et al. The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity. Cell host & microbe. 2010;8(3):271–83.
19. Balmaseda A, Standish K, Mercado JC, Matute JC, Tellez Y, Saborio S, et al. Trends in patterns of dengue transmission over 4 years in a pediatric cohort study in Nicaragua. J Infect Dis. 2010;201(1):5–14. doi: 10.1086/648592 19929380;
20. Kuan G, Gordon A, Aviles W, Ortega O, Hammond SN, Elizondo D, et al. The Nicaraguan pediatric dengue cohort study: study design, methods, use of information technology, and extension to other infectious diseases. Am J Epidemiol. 2009;170(1):120–9. doi: 10.1093/aje/kwp092 19435864;
21. Katzelnick LC, Montoya M, Gresh L, Balmaseda A, Harris E, Neutralizing antibody titers against dengue virus correlate with protection from symptomatic infection in a longitudinal cohort. Proc Natl Acad Sci U S A. 2016;113(3):728–33. doi: 10.1073/pnas.1522136113 26729879;
22. Montoya M, Gresh L, Mercado JC, Williams KL, Vargas MJ, Gutierrez G, et al. Symptomatic versus inapparent outcome in secondary dengue virus infections is influenced by the time interval between infections and study year. PLoS Negl Trop Dis. 2013;7(8):e2357. doi: 10.1371/journal.pntd.0002357 23951377;
23. Wahala WMPB, Kraus AA, Haymore LB, Accavitti-Loper MA, de Silva AM, Dengue virus neutralization by human immune sera: Role of envelope protein domain III-reactive antibody. Virology. 2009;392(1):103–13. http://dx.doi.org/10.1016/j.virol.2009.06.037. 19631955
24. Kraus AA, Messer W, Haymore LB, de Silva AM, Comparison of Plaque- and Flow Cytometry-Based Methods for Measuring Dengue Virus Neutralization. Journal of Clinical Microbiology. 2007;45(11):3777–80. doi: 10.1128/JCM.00827-07 17804661.
25. Padmanabhan R, Vasudevan SG, Dengue Methods and Protocols Preface. Dengue: Methods and Protocols. 2014;1138:27–39.
26. Corbett KS, Katzelnick L, Tissera H, Amerasinghe A, de Silva AD, de Silva AM, Preexisting Neutralizing Antibody Responses Distinguish Clinically Inapparent and Apparent Dengue Virus Infections in a Sri Lankan Pediatric Cohort. Journal of Infectious Diseases. 2015;211(4):590–9. doi: 10.1093/infdis/jiu481 25336728
27. Dejnirattisai W, Wongwiwat W, Supasa S, Zhang X, Dai X, Rouvinsky A, et al. A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus. Nat Immunol. 2015;16(2):170–7. Epub 2014/12/17. doi: 10.1038/ni.3058 25501631.
28. Rouvinski A, Guardado-Calvo P, Barba-Spaeth G, Duquerroy S, Vaney MC, Kikuti CM, et al. Recognition determinants of broadly neutralizing human antibodies against dengue viruses. Nature. 2015. Epub 2015/01/13. doi: 10.1038/nature14130 25581790.
29. Tsai W-Y, Lai C-Y, Wu Y-C, Lin H-E, Edwards C, Jumnainsong A, et al. High-Avidity and Potently Neutralizing Cross-Reactive Human Monoclonal Antibodies Derived from Secondary Dengue Virus Infection. Journal of Virology. 2013;87(23):12562–75. doi: 10.1128/JVI.00871-13 24027331.
30. Tsai WY, Durbin A, Tsai JJ, Hsieh SC, Whitehead S, Wang WK, Complexity of Neutralizing Antibodies against Multiple Dengue Virus Serotypes after Heterotypic Immunization and Secondary Infection Revealed by In-Depth Analysis of Cross-Reactive Antibodies. J Virol. 2015;89(14):7348–62. doi: 10.1128/JVI.00273-15 25972550;
31. Zompi S, Montoya M, Pohl MO, Balmaseda A, Harris E, Dominant Cross-Reactive B Cell Response during Secondary Acute Dengue Virus Infection in Humans. PLoS Negl Trop Dis. 2012;6(3):e1568. 1http://dx.doi.org/10.1371/journal.pntd.0001568. 1288106844; 22448292.
32. de Souza VA, Tateno AF, Oliveira RR, Domingues RB, Araujo ES, Kuster GW, et al. Sensitivity and specificity of three ELISA-based assays for discriminating primary from secondary acute dengue virus infection. J Clin Virol. 2007;39(3):230–3. doi: 10.1016/j.jcv.2007.04.005 17509934.
33. Matheus S, Deparis X, Labeau B, Lelarge J, Morvan J, Dussart P, Discrimination between primary and secondary dengue virus infection by an immunoglobulin G avidity test using a single acute-phase serum sample. J Clin Microbiol. 2005;43(6):2793–7. doi: 10.1128/JCM.43.6.2793-2797.2005 15956399;
34. Sabchareon A, Wallace D, Sirivichayakul C, Limkittikul K, Chanthavanich P, Suvannadabba S, et al. Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. The Lancet. 2012;380(9853):1559–67. http://dx.doi.org/10.1016/S0140-6736(12)61428-7. 1139218052; 22975340.
35. Guy B, Barban V, Mantel N, Aguirre M, Gulia S, Pontvianne J, et al. Evaluation of Interferences between Dengue Vaccine Serotypes in a Monkey Model. The American Journal of Tropical Medicine and Hygiene. 2009;80(2):302–11. 19190230
36. Capeding MR, Tran NH, Hadinegoro SR, Ismail HI, Chotpitayasunondh T, Chua MN, et al. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. Lancet. 2014;384(9951):1358–65. Epub 2014/07/16. doi: 10.1016/S0140-6736(14)61060-6 25018116.
37. Villar L, Dayan GH, Arredondo-Garcia JL, Rivera DM, Cunha R, Deseda C, et al. Efficacy of a tetravalent dengue vaccine in children in Latin America. The New England journal of medicine. 2015;372(2):113–23. Epub 2014/11/05. doi: 10.1056/NEJMoa1411037 25365753.